Literature DB >> 19922795

Relevant shaking stress conditions for antibody preformulation development.

Annette Eppler1, Markus Weigandt, Andrea Hanefeld, Heike Bunjes.   

Abstract

In protein formulation development, shaking stress is often employed to assess the physical stability of antibody formulations against aggregation. Since there are currently no guidelines describing suitable test conditions, very different shaking stress designs are used. These different designs may influence the resulting stability data. The aim of this study was to establish a shaking stress design within the protein range of 2-5mg/ml which can rapidly distinguish between antibody formulations of poor stability and those with potential for further development. Small scale shaking stress experiments were performed with different monoclonal IgG antibodies (as buffered solutions or marketed formulations). Variables were the filling degree of the sample containers, the container type and size and the shaking intensity. The stability of the samples was assessed by visual inspection, UV-VIS spectrophotometric turbidity measurements and size exclusion chromatography. All tested parameters had a strong influence on the stability results. The most discriminating conditions were obtained when shaking of the formulations was performed at 200rpm in a 2ml injection vial filled with 1ml protein solution. This experimental setup led to clearly different stability results for buffered solutions and marketed products. Moreover, this setup required only relatively small amounts of protein solution which is advantageous in prefomulation studies. Copyright (c) 2009 Elsevier B.V. All rights reserved.

Mesh:

Substances:

Year:  2009        PMID: 19922795     DOI: 10.1016/j.ejpb.2009.11.005

Source DB:  PubMed          Journal:  Eur J Pharm Biopharm        ISSN: 0939-6411            Impact factor:   5.571


  9 in total

1.  The use of native cation-exchange chromatography to study aggregation and phase separation of monoclonal antibodies.

Authors:  Shuang Chen; Hollis Lau; Yan Brodsky; Gerd R Kleemann; Ramil F Latypov
Journal:  Protein Sci       Date:  2010-06       Impact factor: 6.725

2.  Structural characterization of IgG1 mAb aggregates and particles generated under various stress conditions.

Authors:  Srivalli N Telikepalli; Ozan S Kumru; Cavan Kalonia; Reza Esfandiary; Sangeeta B Joshi; C Russell Middaugh; David B Volkin
Journal:  J Pharm Sci       Date:  2014-01-22       Impact factor: 3.534

3.  Russell body phenotype is preferentially induced by IgG mAb clones with high intrinsic condensation propensity: relations between the biosynthetic events in the ER and solution behaviors in vitro.

Authors:  Haruki Hasegawa; Christopher E Woods; Francis Kinderman; Feng He; Ai Ching Lim
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 4.  Structure, heterogeneity and developability assessment of therapeutic antibodies.

Authors:  Yingda Xu; Dongdong Wang; Bruce Mason; Tony Rossomando; Ning Li; Dingjiang Liu; Jason K Cheung; Wei Xu; Smita Raghava; Amit Katiyar; Christine Nowak; Tao Xiang; Diane D Dong; Joanne Sun; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2018-12-17       Impact factor: 5.857

5.  Opposite effects of polyols on antibody aggregation: thermal versus mechanical stresses.

Authors:  Shermeen A Abbas; Vikas K Sharma; Thomas W Patapoff; Devendra S Kalonia
Journal:  Pharm Res       Date:  2011-09-27       Impact factor: 4.200

Review 6.  Forced degradation of recombinant monoclonal antibodies: A practical guide.

Authors:  Christine Nowak; Jason K Cheung; Shara M Dellatore; Amit Katiyar; Ram Bhat; Joanne Sun; Gomathinayagam Ponniah; Alyssa Neill; Bruce Mason; Alain Beck; Hongcheng Liu
Journal:  MAbs       Date:  2017-08-30       Impact factor: 5.857

7.  Study on the effect of solution conditions on heat induced-aggregation of human alpha interferon.

Authors:  Faranak Salmannejad; Nastaran Nafissi-Varcheh; Alireza Shafaati; Reza Aboofazeli
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

8.  Fab-dsFv: A bispecific antibody format with extended serum half-life through albumin binding.

Authors:  Emma Davé; Ralph Adams; Oliver Zaccheo; Bruce Carrington; Joanne E Compson; Sarah Dugdale; Michael Airey; Sarah Malcolm; Hanna Hailu; Gavin Wild; Alison Turner; James Heads; Kaushik Sarkar; Andrew Ventom; Diane Marshall; Mark Jairaj; Tim Kopotsha; Louis Christodoulou; Miren Zamacona; Alastair D Lawson; Sam Heywood; David P Humphreys
Journal:  MAbs       Date:  2016-08-17       Impact factor: 5.857

9.  Shocking Data on Parcel Shipments of Protein Solutions.

Authors:  Christine Siska; Paul Harber; Bruce A Kerwin
Journal:  J Pharm Sci       Date:  2019-11-02       Impact factor: 3.534

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.